# Safety-Signal Exploration Report

## 1. Executive summary

This project explored a small synthetic set of adverse-event reports to demonstrate a cautious pharmacovigilance analytics workflow. The analysis cleaned key fields, created age groups, calculated reporting frequencies, estimated a descriptive serious-report proportion, and reviewed drug–event combinations.

The dataset contains **8 reports**, **8 suspected drugs**, and **8 distinct adverse reactions**.

Under the project's descriptive seriousness rule, **3 of 8 reports (37.5%)** were flagged as serious because they had severe/life-threatening severity or a hospitalized outcome.

## 2. Data preparation

The following fields were cleaned and standardized:

- Suspected drug
- Adverse reaction
- Severity
- Patient age / derived age group
- Outcome

Text values were stripped of surrounding whitespace and severity/outcome labels were standardized. Numeric fields were converted safely. An `AgeGroup` field was derived from `PatientAge`.

## 3. Reporting frequency

Each suspected drug appears once in this small sample. Likewise, each adverse reaction appears once.

This means the dataset does not contain a dominant drug or reaction based on raw reporting count.

## 4. Serious-report proportion

The serious-report flag is a **descriptive exercise definition**, not a clinical adjudication. A report was flagged when:

- severity was `Severe` or `Life-Threatening`, **or**
- outcome was `Hospitalized`.

Result: **3/8 = 37.5%**.

## 5. Drug–event combinations

Every observed suspected-drug/adverse-reaction combination occurs once. Therefore, there is **no repeated high-frequency drug–event combination** in this sample.

This is an important finding: the absence of a repeated pair in a tiny dataset does not mean there is no safety concern. It simply means this dataset does not provide enough repeated observations for a frequency-based signal to stand out.

## 6. Signal interpretation

A reporting signal is a pattern that may deserve further expert investigation. It is **not proof of causation**.

Raw reporting frequency can be affected by:

- number of patients exposed
- reporting behavior
- publicity and awareness
- patient characteristics
- underlying disease
- concomitant medicines
- reporting completeness
- duplicate or stimulated reports

Therefore, no causal conclusion is made from this analysis.

## 7. Limitations

1. The sample is very small.
2. It is synthetic and intended for learning.
3. Exposure denominators are unavailable.
4. No causal inference method was applied.
5. Clinical seriousness was not independently adjudicated.
6. Potential confounders such as indication, dose, duration, comorbidities, and concomitant medicines are not modeled.

## 8. Recommended next step

For a real pharmacovigilance workflow, repeated or otherwise notable reporting patterns would be reviewed by qualified safety/pharmacovigilance experts using validated methods and appropriate data sources before any regulatory, clinical, or product decision.

## 9. Conclusion

The project successfully demonstrates a reproducible beginner-level workflow for adverse-event signal exploration: data cleaning, frequency analysis, serious-report proportion, visualization, and cautious interpretation. The supplied sample does not show a repeated high-frequency drug–event pair, so the appropriate conclusion is **no clear frequency-based signal was identified in this small sample**, rather than claiming that no safety signal exists.
